Comprehensive medication guide to Toujeo including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
With insurance, most patients pay $0–$50 per month using the Sanofi Copay Savings Card, or up to Tier 3–4 copay rates on Medicare Part D.
Estimated Cash Pricing
Without insurance, Toujeo costs approximately $175–$550 per pen at retail, though Sanofi's Valyou Savings Program offers it for $35 per 30-day supply.
Medfinder Findability Score
55/100
Summarize with AI
On this page
Toujeo is a brand-name, long-acting basal insulin manufactured by Sanofi. Its active ingredient is insulin glargine at a concentration of 300 units/mL (U-300) — three times more concentrated than Lantus (U-100). Toujeo is FDA-approved for the treatment of type 1 diabetes and type 2 diabetes in adults.
As a basal insulin, Toujeo provides a steady level of insulin over approximately 24–36 hours to help control blood sugar between meals and overnight. It is injected subcutaneously once daily at the same time each day.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Toujeo contains insulin glargine, a recombinant human insulin analog. After subcutaneous injection, the U-300 concentration forms a compact microprecipitate depot under the skin, which dissolves slowly and provides a gradual, prolonged release of insulin over 24–36 hours.
This mechanism lowers blood glucose by stimulating glucose uptake in skeletal muscle and fat tissue while inhibiting glucose production by the liver. Compared to Lantus (U-100 glargine), Toujeo's higher concentration results in a flatter, more even pharmacokinetic profile, which may reduce the risk of hypoglycemia — particularly overnight.
Toujeo SoloStar
1.5 mL prefilled pen containing 450 units total. Delivers 1 — 80 units per injection in 1-unit increments.
Toujeo Max SoloStar
3 mL prefilled pen containing 900 units total. Delivers 2 — 160 units per injection in 2-unit increments. Designed for patients requiring higher doses.
Toujeo receives a findability score of 55 out of 100, meaning it can be moderately difficult to locate in stock at times. While Toujeo is not currently in a formal FDA shortage, the broader insulin glargine market has experienced supply disruptions — notably after the Semglee (biosimilar glargine U-100) phase-out in January 2025, which increased demand for other glargine products like Toujeo.
Some patients have reported regional and intermittent availability issues, particularly for the Toujeo Max SoloStar pen. If your local pharmacy is out of stock, Medfinder can help you search nearby pharmacies that have Toujeo available.
Toujeo can be prescribed by a range of healthcare providers, including:
Toujeo is also available through telehealth consultations, making it accessible for patients who have difficulty visiting a clinic in person.
No, Toujeo is not a controlled substance. It does not have a DEA schedule and is not subject to the same prescribing restrictions as controlled medications. However, Toujeo does require a valid prescription from a licensed healthcare provider. Insulin pens should never be shared between patients, even if the needle is changed, due to the risk of transmitting blood-borne infections.
Like all insulins, Toujeo may cause side effects. The most commonly reported include:
Serious but rare side effects include severe hypoglycemia, hypokalemia (low potassium), and severe allergic reactions. Contact your healthcare provider immediately if you experience any serious symptoms.
Know what you need? Skip the search.
Lantus (Insulin Glargine U-100)
the same active ingredient at a lower concentration; widely available with multiple biosimilars
Basaglar (Insulin Glargine U-100)
a lower-cost biosimilar alternative to Lantus
Semglee / Rezvoglar
additional insulin glargine U-100 biosimilars (note: Semglee was phased out in early 2025)
Tresiba (Insulin Degludec)
an ultra-long-acting basal insulin with up to 42-hour duration
Levemir (Insulin Detemir)
a long-acting basal insulin typically dosed once or twice daily
Prefer Toujeo? We can find it.
Other antidiabetic medications
moderate(sulfonylureas, GLP-1 agonists) — increased risk of hypoglycemia when combined
ACE inhibitors and ARBs
moderatemay enhance blood sugar–lowering effect
Beta-blockers
moderatecan mask the signs and symptoms of hypoglycemia
Thiazolidinediones (TZDs)
moderateincreased risk of heart failure and edema when used with insulin
Corticosteroids
moderatemay reduce insulin effectiveness and raise blood sugar
MAOIs
moderatemay increase hypoglycemia risk
Alcohol
moderatecan unpredictably increase or decrease blood sugar levels
Toujeo is a trusted, long-acting basal insulin that provides smooth, steady blood sugar control for adults with type 1 or type 2 diabetes. While it can sometimes be difficult to find in stock due to broader insulin supply chain pressures, programs like Sanofi's Valyou Savings Program ($35/month) and the Sanofi Copay Savings Card ($0 copay for commercially insured patients) make it affordable for many patients.
If you're struggling to find Toujeo at your pharmacy, Medfinder can help you locate it in stock nearby. Don't hesitate to ask your doctor about alternative insulin options if availability remains an issue in your area.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini